Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis
- PMID: 28779430
- DOI: 10.1007/s10787-017-0383-7
Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis
Abstract
Pulmonary fibrosis is a result of an abnormal wound healing in lung tissue triggered by an excessive accumulation of extracellular matrix proteins, loss of tissue elasticity, and debit of ventilatory function. NKT cells are a major source of Th1 and Th2 cytokines and may be crucial in the polarization of M1/M2 macrophages in pulmonary fibrogenesis. Although there appears to be constant scientific progress in that field, pulmonary fibrosis still exhibits no current cure. From these facts, we hypothesized that NKT cells could influence the development of pulmonary fibrosis via modulation of macrophage activation. Wild type (WT) and NKT type I cell-deficient mice (Jα18-/-) were subjected to the protocol of bleomycin-induced pulmonary fibrosis with or without treatment with NKT cell agonists α-galactosylceramide and sulfatide. The participation of different cell populations, collagen deposition, and protein levels of different cytokines involved in inflammation and fibrosis was evaluated. The results indicate a benign role of NKT cells in Jα18-/- mice and in wild-type α-galactosylceramide-sulfatide-treated groups. These animals presented lower levels of collagen deposition, fibrogenic molecules such as TGF-β and vimentin and improved survival rates. In contrast, WT mice developed a Th2-driven response augmenting IL-4, 5, and 13 protein synthesis and increased collagen deposition. Furthermore, the arginase-1 metabolic pathway was downregulated in wild-type NKT-activated and knockout mice indicating lower activity of M2 macrophages in lung tissue. Hence, our data suggest that NKT cells play a protective role in this experimental model by down modulating the Th2 milieu, inhibiting M2 polarization and finally preventing fibrosis.
Keywords: Alveolar macrophages; Cytokine; Inflammation; Interferon-gamma; Interleukin-4; Natural killer T cells.
Similar articles
-
Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma.Am J Pathol. 2005 Nov;167(5):1231-41. doi: 10.1016/s0002-9440(10)61211-4. Am J Pathol. 2005. PMID: 16251408 Free PMC article.
-
Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis.J Immunol. 2004 May 1;172(9):5782-9. doi: 10.4049/jimmunol.172.9.5782. J Immunol. 2004. PMID: 15100325
-
E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis.Am J Pathol. 2006 Sep;169(3):740-9. doi: 10.2353/ajpath.2006.060086. Am J Pathol. 2006. PMID: 16936251 Free PMC article.
-
Use of human amniotic epithelial cells in mouse models of bleomycin-induced lung fibrosis: A systematic review and meta-analysis.PLoS One. 2018 May 17;13(5):e0197658. doi: 10.1371/journal.pone.0197658. eCollection 2018. PLoS One. 2018. PMID: 29772024 Free PMC article.
-
Sphingolipids in pulmonary fibrosis.Adv Biol Regul. 2015 Jan;57:55-63. doi: 10.1016/j.jbior.2014.09.008. Epub 2014 Oct 13. Adv Biol Regul. 2015. PMID: 25446881 Free PMC article. Review.
Cited by
-
Macrophages: friend or foe in idiopathic pulmonary fibrosis?Respir Res. 2018 Sep 6;19(1):170. doi: 10.1186/s12931-018-0864-2. Respir Res. 2018. PMID: 30189872 Free PMC article. Review.
-
Myeloid cell dynamics in bleomycin-induced pulmonary injury in mice; effects of anti-TNFα antibody.Toxicol Appl Pharmacol. 2021 Apr 15;417:115470. doi: 10.1016/j.taap.2021.115470. Epub 2021 Feb 27. Toxicol Appl Pharmacol. 2021. PMID: 33647319 Free PMC article.
-
Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse.Cell Mol Gastroenterol Hepatol. 2020;9(4):679-688. doi: 10.1016/j.jcmgh.2019.12.008. Epub 2019 Dec 27. Cell Mol Gastroenterol Hepatol. 2020. PMID: 31887435 Free PMC article.
-
Lipid-Reactive T Cells in Immunological Disorders of the Lung.Front Immunol. 2018 Sep 26;9:2205. doi: 10.3389/fimmu.2018.02205. eCollection 2018. Front Immunol. 2018. PMID: 30319649 Free PMC article. Review.
-
Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.Front Immunol. 2022 Mar 18;13:835005. doi: 10.3389/fimmu.2022.835005. eCollection 2022. Front Immunol. 2022. PMID: 35370998 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials